Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well halofuginone hydrobromide works in treating patients
with human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Halofuginone hydrobromide
ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.